KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to -$11.7 million.

  • West Pharmaceutical Services' Cash from Financing Activities rose 8301.89% to -$11.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$185.1 million, marking a year-over-year increase of 7026.98%. This contributed to the annual value of -$185.1 million for FY2025, which is 7026.98% up from last year.
  • Latest data reveals that West Pharmaceutical Services reported Cash from Financing Activities of -$11.7 million as of Q4 2025, which was up 8301.89% from -$11.5 million recorded in Q3 2025.
  • West Pharmaceutical Services' Cash from Financing Activities' 5-year high stood at $300000.0 during Q2 2021, with a 5-year trough of -$271.0 million in Q1 2024.
  • In the last 5 years, West Pharmaceutical Services' Cash from Financing Activities had a median value of -$66.6 million in 2024 and averaged -$86.4 million.
  • As far as peak fluctuations go, West Pharmaceutical Services' Cash from Financing Activities surged by 13333.33% in 2021, and later tumbled by 1216666.67% in 2022.
  • Over the past 5 years, West Pharmaceutical Services' Cash from Financing Activities (Quarter) stood at -$6.2 million in 2021, then crashed by 53.23% to -$9.5 million in 2022, then crashed by 1894.74% to -$189.5 million in 2023, then soared by 63.64% to -$68.9 million in 2024, then soared by 83.02% to -$11.7 million in 2025.
  • Its last three reported values are -$11.7 million in Q4 2025, -$11.5 million for Q3 2025, and -$14.9 million during Q2 2025.